ClinicalTrials.gg
TerminatedNCT03276260Updated Mar 11, 2020

Evaluation of Medasense's PMD-200 During Surgery and Post Anesthesia Care

An observational study in Surgery, Nociceptive Pain and Postoperative Pain, sponsored by Medasense Biometrics Ltd. Terminated at 1 site in Israel. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-03-11.

Sponsored by Medasense Biometrics Ltd · Observational

Why this study was terminated
PI decided not to continue

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
2
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Medasense's Pain Monitoring Device (PMD) is a novel non-invasive, bedside stand alone, continuous monitor that is designed to provide real-time information about changes in the nociception level of patients under general anesthesia during surgical procedures.

The PMD-200 System is based on real-time data acquisition and processing of physiological signals. The system displays the NOL index (a single numerical index) which is computed from recorded physiological parameters based on a proprietary algorithm.

Read the detailed description

The aim of this observational study is to evaluate the pattern of the NOL index during surgery in the anesthetized patient and during the post-operative period in the awake patient.

Up to 100 patients scheduled for elective surgery under general, regional and local anesthesia and sedation, who meet all the inclusion and none of the exclusion criteria, will be enrolled after signing informed consent.

02

Conditions studied

  • Surgery
  • Nociceptive Pain
  • Postoperative Pain
03

In context

Nociceptive Pain

96 studies on the registry are indexed under Nociceptive Pain; 18 are open to participants now.

This study's enrollment of 2 is below the median of 74 across 32 observational studies indexed under Nociceptive Pain.

Browse Nociceptive Pain studies →

Lead sponsor

Medasense Biometrics Ltd is the lead sponsor of 12 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Up to 100 patients scheduled for elective surgery under general, regional and local anesthesia and sedation, who meet all the inclusion and none of the exclusion criteria, will be enrolled after signing informed consent.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Both genders
  • Age 18 - 75 years
  • 1-3
  • Elective surgery

Exclusion criteria

Exclusion Criteria:

  • History of severe cardiac arrhythmia
  • Abuse of alcohol or illicit drugs
  • Preoperative opioid consumption for > 1 week
  • History of mental retardation or any mental disease diagnosis
  • Under sedation protocol - Patients with difficult spontaneous ventilation ( for e.g. patients with sleep apnea) will be excluded.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
2 participants (actual)
Patient registry
No

Interventions

  • DevicePMD-200

    Patient will be connected to PMD-200 by finger-probe before induction of anesthesia or sedation. Recording will continue during surgery until extubation or awakening. Recording will be initiated again as soon as the patient arrives to the PACU until discharge to the surgical ward or home.

06

What researchers measure

Primary outcomes

  1. The ability of NOL index to change in response to noxious and non noxious stimuli as well as in response to analgesic administration.

    Time frame: At time of surgery. 1 minute before and 1 minute after painful stimuli (for instance: intubation, skin incision, trocar insertion

  2. Specificity and sensitivity of the NOL index for detecting nociception as evaluated by receiver operating characteristics curve (ROC) analysis.

    The calculated area under the graph of change in NOL values in response to a painful stimulus, as mentioned in Outcome 1.

    Time frame: At time of surgery, between the anaesthesia induction and extubation.

Secondary outcomes

  1. The change in NOL Index in response to pre-defined non noxious and noxious stimuli during surgery in the anesthetized patient.

    Pre-defined noxious events - laryngoscopy and intubation, skin incision or first trocar.

    Time frame: At time of surgery: pre-defined non noxious period - a period of 2 minutes with no noxious event with a minimal time period of 3 min prior and following laryngoscopy and intubation, skin incision or first trocar insertion.

  2. The change in NOL index in response to administration of analgesics.

    Time frame: At time of surgery, 1min before versus 1 min after administration of analgesics drugs.

  3. Total fentanyl administration during surgery and anaesthesia and frequency of bolus administration.

    Time frame: At time of surgery, between the anaesthesia induction and extubation.

  4. Total time with mean arterial pressure (MAP) < 65 mmHg and correlation to NOL values during surgery and anaesthesia.

    Time frame: At time of surgery, between the anaesthesia induction and extubation.

  5. Total analgesics administration during PACU (arrival to discharge) and frequency of administration

    Time frame: Throughout PACU (Post Anesthesia Care Unit) stay, between entering PACU to discharge, an average of 2.5 hours.

  6. NOL values during stay in PACU in the awake patient (arrival to discharge)

    The NOL will be calculated via the investigational device.

    Time frame: Throughout PACU (Post Anesthesia Care Unit) stay, between entering PACU to discharge, an average of 2.5 hours.

  7. Patients' NRS (numerical rating scale ) values during stay in PACU (arrival to discharge).

    NRS will be recorded every 15 min in the PACU

    Time frame: Throughout PACU (Post Anesthesia Care Unit) stay, between entering PACU to discharge, an average of 2.5 hours.

  8. Sedation scores during stay in PACU (arrival to discharge).

    Sedation scores will be recorded every 30 min in the PACU

    Time frame: Throughout PACU (Post Anesthesia Care Unit) stay, between entering PACU to discharge, an average of 2.5 hours.

  9. Time to first analgesic request or administration in PACU.

    Time frame: Throughout PACU (Post Anesthesia Care Unit) stay, between entering PACU to discharge, an average of 2.5 hours.

  10. Number of opioid adverse effects in PACU (nausea and vomiting, pruritus, desaturation, respiratory depression, apnea).

    Time frame: Throughout PACU (Post Anesthesia Care Unit) stay, between entering PACU to discharge, an average of 2.5 hours.

  11. Time of readiness to discharge from PACU

    This time will be recorded since it may be different from the actual time of discharge which may be prolonged due to non-medical reasons.

    Time frame: Throughout PACU (Post Anesthesia Care Unit) stay, between entering PACU to discharge, an average of 2.5 hours.

  12. The correlation between NOL values during surgery and anesthesia to NOL values during the post-operative period.

    The NOL will be calculated via the investigational device.

    Time frame: From the anaesthesia induction till the discharge from the PACU, an average of 5-6 hours.

07

Study locations

1 site
  • Rambam Health Care Campus
    Haifa, 31096, Israel
08

References and documents

Publications

  • Edry R, Recea V, Dikust Y, Sessler DI. Preliminary Intraoperative Validation of the Nociception Level Index: A Noninvasive Nociception Monitor. Anesthesiology. 2016 Jul;125(1):193-203. doi: 10.1097/ALN.0000000000001130. PubMed 27171828 ↗
  • Martini CH, Boon M, Broens SJ, Hekkelman EF, Oudhoff LA, Buddeke AW, Dahan A. Ability of the nociception level, a multiparameter composite of autonomic signals, to detect noxious stimuli during propofol-remifentanil anesthesia. Anesthesiology. 2015 Sep;123(3):524-34. doi: 10.1097/ALN.0000000000000757. PubMed 26154185 ↗
  • Treister R, Kliger M, Zuckerman G, Aryeh IG, Eisenberg E. Differentiating between heat pain intensities: the combined effect of multiple autonomic parameters. Pain. 2012 Sep;153(9):1807-1814. doi: 10.1016/j.pain.2012.04.008. Epub 2012 May 29. PubMed 22647429 ↗
  • Ben-Israel N, Kliger M, Zuckerman G, Katz Y, Edry R. Monitoring the nociception level: a multi-parameter approach. J Clin Monit Comput. 2013 Dec;27(6):659-68. doi: 10.1007/s10877-013-9487-9. Epub 2013 Jul 9. PubMed 23835792 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in Apr 2019, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2017
First posted
Sep 8, 2017
StartActual
Jan 1, 2018
Primary completionActual
Apr 30, 2019
CompletionActual
Apr 30, 2019
Last update
Mar 11, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03276260
Lead sponsor
Medasense Biometrics Ltd
Responsible party
Sponsor
First posted
Sep 8, 2017
Start date
Jan 1, 2018
Primary completion
Apr 30, 2019
Completion
Apr 30, 2019
Last update
Mar 11, 2020

Study contacts

Ruth Edry, MD
principal investigator · Rambam Health Care Campus

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion